Krystal Biotech, Inc. Q2 2026 Earnings Recap

Krystal Biotech’s shares fell 4.8% following the quarter, driven primarily by a disappointing outlook on pricing and reimbursement progress in Europe leading to a revenue reserve in Germany. Despite operational momentum, investor concerns over continued market access hurdles and muted near-term revenue growth weighed on sentiment.

Key Takeaways

• Europe and Japan revenues remained broadly flat in Q2, impacted by a reserve provision related to uncertain pricing outcomes in Germany.
• Ongoing reimbursement negotiations in key EU markets like Germany, Italy, and Spain are delaying sustained revenue growth, with formal pricing decisions expected to continue through 2026 and 2027.
• U.S. net revenue was $91.6 million, reflecting steady commercial traction and expansion into community settings.
• International launches show growth in patient and treatment volumes but face operational challenges, including fragmented care centers in Germany and access restrictions in France and Japan.
• Multiple upcoming regulatory submissions in other countries are planned, but market access remains a significant near-term obstacle to revenue scaling.